Proprietary AI analyst is now available

d1000 Valuation Multiples

Discover revenue and EBITDA valuation multiples for d1000 and similar public comparables like BlueMTec, MARX Biotech, Talea Group, PetMeds and more.

d1000 Overview

About d1000

D1000 Varejo Farma Participacoes SA invests in national or foreign pharmaceutical retail companies.


Founded

2010

HQ

Brazil

Employees

N/A

Sectors

Financials (FY)

Revenue: $525M
EBITDA: $41M

EV

$170M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

d1000 Financials

d1000 reported last fiscal year revenue of $525M and EBITDA of $41M.

In the same fiscal year, d1000 generated $150M in gross profit, $41M in EBITDA, and $4M in net income.


d1000 P&L

In the most recent fiscal year, d1000 reported revenue of $525M and EBITDA of $41M.

d1000 is profitable as of last fiscal year, with gross margin of 29%, EBITDA margin of 8%, and net margin of 1%.

See analyst estimates for d1000
Last FY202320242025202620272028
Revenue$525M$344M$426M$525M
Gross Profit$150M$109M$130M$150M
Gross Margin29%32%31%29%
EBITDA$41M$31M$36M$41M
EBITDA Margin8%9%8%8%
EBIT Margin3%3%3%3%
Net Profit$4M$4M$5M$4M
Net Margin1%1%1%1%
Net Debt$12M---

Financial data powered by Morningstar, Inc.

d1000 Stock Performance

d1000 has current market cap of $69M, and enterprise value of $170M.

Market Cap Evolution


d1000's stock price is $1.37.

d1000 share price decreased by 0.6% in the last 30 days, and increased by 37.4% in the last year.

d1000 has an EPS (earnings per share) of $0.09.

See more trading valuation data for d1000
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$170M$69M-1.7%-0.6%-4.0%37.4%$0.09

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

d1000 Valuation Multiples

d1000 trades at 0.3x EV/Revenue multiple, and 4.1x EV/EBITDA.

See NTM and 2027E valuation multiples for d1000

d1000 Financial Valuation Multiples

As of June 5, 2026, d1000 has market cap of $69M and EV of $170M.

d1000 has a P/E ratio of 15.6x.

Last FY202320242025202620272028
EV/Revenue0.3x0.5x0.4x0.3x
EV/EBITDA4.1x5.4x4.8x4.1x
EV/EBIT10.3x16.8x13.7x10.3x
EV/Gross Profit1.1x1.6x1.3x1.1x
P/E15.6x16.5x13.6x15.6x
EV/FCF11.9x9.8x10.6x11.9x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified d1000 Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

d1000 Margins & Growth Rates

In the most recent fiscal year, d1000 reported gross margin of 29%, EBITDA margin of 8%, and net margin of 1%.

See estimated margins and future growth rates for d1000

d1000 Margins

Last FY20242025202720282029
Gross Margin29%31%29%
EBITDA Margin8%8%8%
EBIT Margin3%3%3%
Net Margin1%1%1%
FCF Margin3%4%3%

d1000 Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth24%23%
Gross Profit Growth20%15%
EBITDA Growth13%16%
EBIT Growth23%33%
Net Profit Growth21%(13%)
FCF Growth(7%)(11%)

Data powered by FactSet, Inc. and Morningstar, Inc.

d1000 Operational KPIs

Access forward-looking KPIs for d1000
Last FY202320242025202620272028
S&M Expenses to Revenue23%25%24%23%
G&A Expenses to Revenue3%4%4%3%
Opex to Revenue25%29%28%25%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

d1000 Competitors

d1000 competitors include BlueMTec, MARX Biotech, Talea Group, PetMeds, SC Ropharma, Farmacosmo, Pilulka Lekarny, Rise, Wellgistics Health and Profarma.

Most d1000 public comparables operate across Pharmacies.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
BlueMTec0.5x-79.2x-
MARX Biotech5.0x-34.7x-
Talea Group0.6x-24.4x-
PetMeds0.1x0.1x(0.8x)(0.5x)
SC Ropharma0.2x-4.4x-
Farmacosmo0.4x-62.9x-
Pilulka Lekarny0.3x-(8.1x)-
Rise4.8x4.2x17.8x-

This data is available for Pro users. Sign up to see all d1000 competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About d1000

When was d1000 founded?d1000 was founded in 2010.
Where is d1000 headquartered?d1000 is headquartered in Brazil.
Is d1000 publicly listed?Yes, d1000 is a public company listed on B3.
What is the stock symbol of d1000?d1000 trades under DMVF3 ticker.
When did d1000 go public?d1000 went public in 2020.
Who are competitors of d1000?d1000 main competitors include BlueMTec, MARX Biotech, Talea Group, PetMeds, SC Ropharma, Farmacosmo, Pilulka Lekarny, Rise, Wellgistics Health, Profarma.
What is the current market cap of d1000?d1000's current market cap is $69M.
What is the current revenue of d1000?d1000's last fiscal year revenue is $525M.
What is the current EV/Revenue multiple of d1000?Current revenue multiple of d1000 is 0.3x.
Is d1000 profitable?No, d1000 is not profitable.
How many companies d1000 has acquired to date?d1000 hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies d1000 has invested to date?d1000 hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to d1000

Lists including d1000

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial